самостоятельная работа нахождение процента от числа
Главное меню:
Интересное
самостоятельная работа нахождение процента от числа, ENJAYMO® (sutimlimab-jome) | Dosing and Administration, ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing, Enjaymo Dosage Guide - Drugs.com, LABEL - accessdata.fda.gov, HIGHLIGHTS OF PRESCRIBING INFORMATION - Sanofi, ENJAYMO- sutimlimab-jome injection, solution, concentrate - DailyMed, Enjaymo (sutimlimab) dosing, indications, interactions, adverse effects .
The ENJAYMO Patient Solutions Co-Pay program (the “Program”) is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law and savings may vary depending on patients’ out-of-pocket costs. Recordati Rare Diseases reserves the right to modify or terminate the Program at any time without notice. Patients will receive all Program details upon registration. TRICARE is a registered trademark of the Department of Defense, Defense Health Agency. All rights reserved., The recommended dosing regimen for adults with Cold Agglutinin Disease (CAD) consists of an initial dose and a dose 1 week later, followed by 1 dose every 2 weeks. ENJAYMO is for IV infusion only., The ENJAYMO dosing schedule is designed to provide a continuous level of medicine. ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter..
Detailed dosage guidelines and administration information for Enjaymo (sutimlimab-jome). Includes dose adjustments, warnings and precautions., The recommended dosage of ENJAYMO for patients with CAD is based on body weight. For patients weighing 39 kg to less than 75 kg, the recommended dose is 6,500 mg and for patients weighing 75 kg or more, the recommended dose is 7,500 mg. Administer ENJAYMO intravenously weekly for the first two weeks, with administration every two weeks thereafter., Dosage interruptions of ENJAYMO due to an adverse reaction occurred in 7/24 patients. Adverse reactions which required dosage interruption included pneumonia, COVID-19 pneumonia, abdominal pain upper, urinary tract infection bacterial, urosepsis, acrocya-nosis, viral infection, blood creatinine increased and infusion-related reaction., ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]., Medscape - Cold agglutinin disease dosing for Enjaymo (sutimlimab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information., Enjaymo should be administered at the recommended dose regimen time points, or within two days of these time points (see section 4.4). Enjaymo is intended for continuous use as chronic therapy only, unless the discontinuation of Enjaymo is clinically indicated. Missed dose.